Cargando…

P1013: CBL MUTATION MAY BE ASSOCIATED WITH THE ONSET OF MYELOPROLIFERATIVE NEOPLASMS WITH MICROVASCULAR DISORDERS: A SINGLE-CENTRE EXPERIENCE

Detalles Bibliográficos
Autores principales:	Micucci, Giorgia, Mattei, Agnese, Poggiaspalla, Monica, Musuraca, Gerardo, Frabetti, Federica, Foca, Flavia, Giordano, Giulio, Napolitano, Mariasanta, Lucchesi, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431457/ http://dx.doi.org/10.1097/01.HS9.0000970956.43764.3d

Ejemplares similares

Circulating Endothelial Cell Levels Correlate with Treatment Outcomes of Splanchnic Vein Thrombosis in Patients with Chronic Myeloproliferative Neoplasms
por: Giordano, Giulio, et al.
Publicado: (2022)

P992: OUTCOMES OF GLOBAL COAGULATION ASSAYS IN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS WITH RESPECT TO THEIR CLINICAL AND GENETIC DETERMINANTS OF CLONAL EVOLUTION
por: Lucchesi, A., et al.
Publicado: (2022)

Unexpected low expression of platelet fibrinogen receptor in patients with chronic myeloproliferative neoplasms: how does it change with aspirin?
por: Lucchesi, Alessandro, et al.
Publicado: (2019)

Platelets Contribution to Thrombin Generation in Philadelphia-Negative Myeloproliferative Neoplasms: The “Circulating Wound” Model
por: Lucchesi, Alessandro, et al.
Publicado: (2021)

Genetics and Pathogenetic Role of Inflammasomes in Philadelphia Negative Chronic Myeloproliferative Neoplasms: A Narrative Review
por: Di Battista, Valeria, et al.
Publicado: (2021)

Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders
por: Naramura, Mayumi, et al.
Publicado: (2011)

Oral high-dose sucrosomial iron vs intravenous iron in sideropenic anemia patients intolerant/refractory to iron sulfate: a multicentric randomized study
por: Giordano, Giulio, et al.
Publicado: (2020)

Myeloproliferative neoplasms
por: Cross, Nick
Publicado: (2019)

Myeloproliferative neoplasms
por: Kiladjian, Jean-Jacques
Publicado: (2018)

Genetic regulation of iron homeostasis in sideropenic patients with mild COVID-19 disease under a new oral iron formulation: Lessons from a different perspective
por: Giordano, Giulio, et al.
Publicado: (2022)

Epigenetics in Myeloproliferative Neoplasms
por: McPherson, Suzanne, et al.
Publicado: (2017)

Aetiology of Myeloproliferative Neoplasms
por: McMullin, Mary Frances, et al.
Publicado: (2020)

The microenvironment in myeloproliferative neoplasm
por: Méndez-Ferrer, Simón, et al.
Publicado: (2018)

Spleen in myeloproliferative neoplasms
por: Barosi, Giovanni
Publicado: (2018)

Epigenetics in myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2023)

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
por: Tefferi, A
Publicado: (2010)

VAV1-Cre mediated hematopoietic deletion of CBL and CBL-B leads to JMML-like aggressive early-neonatal myeloproliferative disease
por: An, Wei, et al.
Publicado: (2016)

Immune Thrombocytopenia in Antiphospholipid Syndrome: Is It Primary or Secondary?
por: Tomasello, Riccardo, et al.
Publicado: (2021)

Deactylase inhibition in myeloproliferative neoplasms
por: Mithraprabhu, Sridurga, et al.
Publicado: (2010)

Guidelines for the management of myeloproliferative neoplasms
por: Choi, Chul Won, et al.
Publicado: (2015)

The Hematopoietic Niche in Myeloproliferative Neoplasms
por: Schmitt-Graeff, Annette H., et al.
Publicado: (2015)

Calreticulin Mutations in Myeloproliferative Neoplasms
por: Lavi, Noa
Publicado: (2014)

Targeted therapies for myeloproliferative neoplasms
por: Li, Bing, et al.
Publicado: (2019)

Apoptosis deregulation in myeloproliferative neoplasms
por: Tognon, Raquel, et al.
Publicado: (2013)

Mutant Calreticulin in the Myeloproliferative Neoplasms
por: Prins, Daniel, et al.
Publicado: (2020)

Experimental Modeling of Myeloproliferative Neoplasms
por: Lanikova, Lucie, et al.
Publicado: (2019)

Novel therapeutics in myeloproliferative neoplasms
por: Venugopal, Sangeetha, et al.
Publicado: (2020)

Molecular pathogenesis of the myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2021)

Understanding Aberrant Signaling to Elude Therapy Escape Mechanisms in Myeloproliferative Neoplasms
por: Bochicchio, Maria Teresa, et al.
Publicado: (2022)

Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms
por: Person, Fermin, et al.
Publicado: (2021)

Le synchrotron injecteur accélère 1013 ppi
Publicado: (1974)

macOS support essentials 10.13
por: Dreyer, Arek, et al.
Publicado: (2018)

Philadelphia-negative chronic myeloproliferative neoplasms
por: Bittencourt, Rosane Isabel, et al.
Publicado: (2012)

CALR mutation characterization in myeloproliferative neoplasms
por: Bilbao-Sieyro, Cristina, et al.
Publicado: (2016)

Genetic–pathologic characterization of myeloproliferative neoplasms
por: Kim, Yonggoo, et al.
Publicado: (2016)

The Role of New Technologies in Myeloproliferative Neoplasms
por: Palumbo, Giuseppe A., et al.
Publicado: (2019)

Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms
por: Kjær, Lasse
Publicado: (2020)

Hypercalcemia as a biomarker of myeloproliferative neoplasms?
por: Langabeer, Stephen E.
Publicado: (2019)

Cytokines frequently implicated in myeloproliferative neoplasms
por: Wang, Yingying, et al.
Publicado: (2019)

Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms
por: Palomo, Laura, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qqco6qet9th50drhb4u9a4prta